NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 28.31 against a street estimate of 26.44 — a beat of 7.1%.
with an average price target of ₹7,363.63.
CONFIDENT Q1 FY27 beat expectations with 24% profit growth YoY despite solvent cost inflation and geopolitical supply chain disruption. Custom synthesis now 60% of revenue; three major CapEx projects nearing validation completion. Q1 FY27 Geographic exposure stable; West Asia supply chain disruption managed via 3-month rolling inventory buffer strategy. Analysts pressed for quantified validation-to-commercial ramp metrics and CapEx revenue contribution; management cited confidentiality agreements and case-by-case variability, declining numerical specificity. Solvent cost isolation question rebuffed as non-generalizable. Margin trajectory treated as year-on-year, not quarterly. 2026-08-01…
Full summary in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Divi's Laboratories Limited — free to start.
Google PlayApp StoreData updated 2026-08-05.